Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-dose Phase 1 PK study of MAR-001- HLE (a half-life-extended version of MAR001) in healthy volunteers

Next Previous
Trial Profile

A single-dose Phase 1 PK study of MAR-001- HLE (a half-life-extended version of MAR001) in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MAR-001 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Pharmacokinetics

Most Recent Events

  • 11 Feb 2026 New trial record
  • 13 Jan 2026 According to a Marea Therapeutics media release, the company has aligned on a streamlined Phase 1 PK bridging strategy to support the advancement of MAR001-HLE (a half-life-extended version of MAR001) into Phase 3, following a Type B meeting with the USFDA in Nov 2025. A single-dose Phase 1 PK study in healthy volunteers is planned for 2026, with PK data expected by YE-2026. An IND filing for MAR001-HLE is anticipated in 2026, with a clinical bridging study planned for 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top